




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Interventions and Vascular Medicine</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=4e7de144-8d5e-4458-886d-76ce2c5a0b66</link>
        <description>Clinical Topic Feed: Interventions and Vascular Medicine</description>
        <language>en</language>

        

                <item>
                    <title>New Studies Add to Evidence Involving Optimal Treatment of Patients Post-Ischemic Stroke</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/18/18/10/New-Studies-Add-to-Evidence</link>                    <description>Treatment of patients following ischemic stroke was the focus of three separate studies published in JAMA, two of which involved use of intravenous tenecteplase and the other involving thrombectomy plus intra-arterial alteplase.</description>
                    <pubdate>1779219300000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Can Cardiorespiratory Fitness Lead to Longer Lifespans?</title>
<link>/Latest-in-Cardiology/Articles/2026/04/29/14/55/eagles-eye-view-29apr2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at endovascular therapy for post-thrombotic syndrome and how it reduces severity and improves quality of life.</description>
                    <pubdate>1777474620000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>C-TRACT: Endovascular Therapy For Post-Thrombotic Syndrome Reduces Severity, Improves QOL</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/04/21/16/07/C-TRACT</link>                    <description>Endovascular therapy added to standard care for post-thrombotic syndrome was associated with improved syndrome severity and quality of life (QOL) at six months compared with standard care alone in patients with moderate or severe post-thrombotic syndrome and iliac vein-obstruction...</description>
                    <pubdate>1776787680000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>HOST-EXAM: Clopidogrel vs. Aspirin Monotherapy at 10 Years Post PCI</title>
<link>/Latest-in-Cardiology/Articles/2026/04/07/19/53/host-exam-acc-2026</link>                    <description>Clopidogrel monotherapy after PCI was associated with a significantly lower composite risk of all-cause death, nonfatal MI, stroke, readmission for acute coronary syndrome (ACS) and major bleeding compared with aspirin monotherapy, according to 10-year follow-up results of the HOST-EXAM trial presented as featured clinical research at ACC.26 and published simultaneously in The Lancet.</description>
                    <pubdate>1775593440000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>SURVIV: mViV vs. rMVR For Mitral Bioprosthetic Valve Dysfunction</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-surviv-acc-2026</link>                    <description>Among patients with a failed mitral bioprosthetic valve, transcatheter mitral valve-in-valve (mVIV) treatment was associated with a lower rate of death or disabling stroke at one year compared with standard repeat mitral valve replacement surgery (rMVR), according to results from the SURVIV study presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans.</description>
                    <pubdate>1774818000000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>STEMI-DTU: Left Ventricular Unloading in Anterior STEMI Without Shock</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-930am-stemidtu-acc-2026</link>                    <description>Compared with immediate PCI alone, the combination of mechanical left ventricular (LV) unloading using a transvalvular micro-axial flow pump (TV-mAFP) plus delayed PCI did not reduce infarct size in patients with anterior STEMI without cardiogenic shock, according to findings from the STEMI-DTU trial presented at ACC.26 and simultaneously published in JACC.</description>
                    <pubdate>1774708320000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>DOBERMANN: Are Tocilizumab, Dobutamine Effective in Reducing CS Risk in Patients With AMI?</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/03/19/17/12/Dobermann</link>                    <description>Two brief reports in JACC on the DOBERMANN-T and DOBERMANN-D trials found that among patients with acute myocardial infarction (AMI) at increased risk of cardiogenic shock (CS), early interleukin 6 (IL 6) receptor inhibition with tocilizumab safely reduced systemic inflammation but showed inconclusive effects on NT proBNP. In contrast, early dobutamine infusion did not lower NT proBNP levels but did reduce systolic blood pressure (SBP) without raising safety concerns.</description>
                    <pubdate>1773942840000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Pre-Hospital Glycoprotein IIb/IIIa Inhibition With Zalunfiban in STEMI</title>
<link>/Latest-in-Cardiology/Articles/2026/03/16/16/27/Pre-Hospital-Glycoprotein-IIb-IIIa-Inhibition-With-Zalunfiban-in-STEMI</link>                    <description>The CELEBRATE (CeleCor Blinded Randomized Trial in ST-Elevation Myocardial Infarction) trial was a phase 3, multicenter, double-blind, placebo-controlled study that evaluated the efficacy and safety of a single subcutaneous injection of zalunfiban (CeleCor Therapeutics), a novel glycoprotein IIb/IIIa inhibitor...</description>
                    <pubdate>1773751800000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: New Guidelines for Treatment of Acute PE</title>
<link>/Latest-in-Cardiology/Articles/2026/02/24/16/30/eagles-eye-view-24feb2025</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered.</description>
                    <pubdate>1772031600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC, AHA Release First-Ever Guideline For Treatment and Management of Acute PE</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/02/17/14/32/ACC-AHA-Release-First-Ever-Guideline-For-Treatment-and-Management-of-Acute-PE</link>                    <description>The new ACC/AHA Guideline for the Evaluation and Management of Acute Pulmonary Embolism (PE) in Adults is a de novo document offering comprehensive, evidence&#226;€‘based recommendations for the evaluation, management and follow&#226;€‘up of adults with acute PE.</description>
                    <pubdate>1771527600000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>